Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.
Journal Article (Clinical Trial;Journal Article)
Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60 mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or clinical response. Six of these demonstrated an event-free response that was maintained for periods of between 7 and 26 months.
Full Text
Duke Authors
Cited Authors
- Moseley, RP; Davies, AG; Richardson, RB; Zalutsky, M; Carrell, S; Fabre, J; Slack, N; Bullimore, J; Pizer, B; Papanastassiou, V
Published Date
- October 1990
Published In
Volume / Issue
- 62 / 4
Start / End Page
- 637 - 642
PubMed ID
- 2223581
Pubmed Central ID
- PMC1971477
International Standard Serial Number (ISSN)
- 0007-0920
Digital Object Identifier (DOI)
- 10.1038/bjc.1990.345
Language
- eng
Conference Location
- England